U.S. Group Wants India Removed From Import-Preference List Over CL Use
This article was originally published in PharmAsia News
Executive Summary
A group is urging removal of India from the U.S. Generalized System of Preferences program of beneficial import treatment, citing regulations that harm competitors, including those in the pharmaceutical industry.